Alterity Therapeutics (ATHE) has released an update.
Alterity Therapeutics, a biotechnology company focused on neurodegenerative disease treatments, will feature in a fireside chat at the 2024 Maxim Healthcare Virtual Summit. The company’s CEO will discuss their lead drug ATH434, currently in Phase 2 trials for Multiple System Atrophy, showcasing Alterity’s innovative approach in the biotech sector.
For further insights into ATHE stock, check out TipRanks’ Stock Analysis page.
